PA
CASC

Perceptive Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Perceptive Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,966
Closed -$8K – 185
2017
Q1 		$8K Sell
1,966
-544,532
-100% -$2.29M ﹤0.01% 153
2016
Q4 		$2.35M Sell
546,498
-22,522
-4% -$146K 0.17% 79
2016
Q3 		$5.6M Hold
569,020
– – 0.36% 64
2016
Q2 		$3.22M Hold
569,020
– – 0.22% 72
2016
Q1 		$4.33M Hold
569,020
– – 0.38% 61
2015
Q4 		$7.58M Sell
569,020
-22,130
-4% -$381K 0.56% 42
2015
Q3 		$1.38M Buy
591,150
+33,334
+6% +$683K 0.11% 92
2015
Q2 		$12.5M Buy
557,816
+403,649
+262% +$6.38M 0.75% 35
2015
Q1 		$1.51M Buy
154,167
+100,000
+185% +$981K 0.12% 89
2014
Q4 		$618K Hold
54,167
– – 0.05% 112
2014
Q3 		$624K Buy
54,167
+5,370
+11% +$82K 0.06% 91
2014
Q2 		$949K Sell
48,797
-41,703
-46% -$736K 0.09% 82
2014
Q1 		$1.62M Buy
90,500
+7,167
+9% +$118K 0.17% 75
2013
Q4 		$880K Buy
83,333
+2,916
+4% +$32.6K 0.11% 68
2013
Q3 		$994K Buy
+80,417
New +$846K 0.08% 72

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Perceptive Advisors's CASC Position: Q2 2017 in Review

Perceptive Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 1,966 shares — an estimated $8K sold.

Perceptive Advisors first reported a position in CASC in Q3 2013 and held it in 15 quarters. The position peaked at $12.5M in Q2 2015. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • Perceptive Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Perceptive Advisors sold 1,966 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $8K.
  • Perceptive Advisors first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 15 quarters.
  • Perceptive Advisors's Cascadian Therapeutics, Inc. position peaked at $12.5M in Q2 2015.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.